A clinical trial on THAZUTHALAI ILAI CHOORANAM in the management of KUMBAVADHAM( PERIARTHRITIS)

A prospective open labelled non randomized phase II clinical trial of THAZHUTHALAI ILAI CHOORANAM in the management of KUMBAVADHAM (PERIARTHRITIS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040038

Enrollment

Registered

2022-02-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M750- Adhesive capsulitis of shoulder

Interventions

Intervention1: THAZHUTHALAI ILAI CHOORANAM: 2g/twice a day/orally with Hot water,45 days Control Intervention1: Nil: 0

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient having main symptoms of shoulder pain, numbness, wasting in the shoulder region and arms, restricted movement of upperlimbs,loss of abduction and forward flexing, stiffness of the shoulder joint 2.Diabetes mellitus 3.patient willing for doing laboratory investigations and X ray, imaging

Exclusion criteria

Exclusion criteria: 1.Rheumatoid arthritis 2. Ischemical heart disease 3.Hypertension 4. Pregnancy and lactating mother 5.Recent shoulder dislocation 6. Sub acromial bursitis

Design outcomes

Primary

Measure	Time frame
If during treatment or after treatment Redution of the signs and symptoms of 1.shoulder joint pain 2.shoulder stiffness 3.Inability to raise arm 4.Limited shoulder mobility and wasting in shoulder region and arms and numbness 5.Radiating pain down arm 6.Restricted movements of upperlimbs. 7. Loss of abduction and forward flexing and external rotation and achieving better Oxford shoulder score (40-48)Timepoint: 45 days	—

Measure

Time frame

If during treatment or after treatment Redution of the signs and symptoms of 1.shoulder joint pain 2.shoulder stiffness 3.Inability to raise arm 4.Limited shoulder mobility and wasting in shoulder region and arms and numbness 5.Radiating pain down arm 6.Restricted movements of upperlimbs. 7. Loss of abduction and forward flexing and external rotation and achieving better Oxford shoulder score (40-48)Timepoint: 45 days

—

Secondary

Measure	Time frame
1. To evaluate the biochemical physico-chemical analysis of clinical trail drug 2. To evaluate the antimicrobial activity of trail drug 3.To evaluate the safety profile for acute and subacute toxicity of the trail drug Thazhuthalai ilai chooranam 4. To Evaluate pharmacological analysis of the clinical trail drug 5. To evaluate siddha parameters and modern parameters during the treatment of kumbavadham with trail drug 6. To evaluate the statistical analysis of the clinical trail drug Thazhuthalai ilai chooranam 7. To evaluate the powder of microscopic study and HTPLC of the trail drugTimepoint: 45days	—

Measure

Time frame

1. To evaluate the biochemical physico-chemical analysis of clinical trail drug 2. To evaluate the antimicrobial activity of trail drug 3.To evaluate the safety profile for acute and subacute toxicity of the trail drug Thazhuthalai ilai chooranam 4. To Evaluate pharmacological analysis of the clinical trail drug 5. To evaluate siddha parameters and modern parameters during the treatment of kumbavadham with trail drug 6. To evaluate the statistical analysis of the clinical trail drug Thazhuthalai ilai chooranam 7. To evaluate the powder of microscopic study and HTPLC of the trail drugTimepoint: 45days

—

Countries

India

Contacts

Public ContactProfDr A Manoharan MDs ph D

Government Siddha Medical College and Hospital

drmanoharan25@gmail.com9443886700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026